Cheng Joan Q Liu

6346101, Feb 12, 2002

Jun 4, 1997

08/887196

Robert R. Alfano - Bronx NY
Cheng Hui Liu - Flushing NY

Research Foundation of City College of New York - New York NY

A61B 1818

606 15, 606 1, 606 10, 606 13, 606 17, 604 19, 604 20, 128898

A photon-mediated technique for introducing biological materials into cells and/or cellular components. The technique may be used to introduce nucleic acids, such as DNA and RNA, proteins or other biological materials into mammalian cells (as well as into other animal and plant cells), which materials may then flow into the nuclei of the cells. The technique uses picosecond or femtosecond light pulses propagating in the UV, visible and near infrared wavelength regions with powers on the order of 1Ã10 W/cm. In practice, the desired biological materials are coated on the end of the inner core of a single mode fiber or the ring core of a fiber in a fiber array. Each fiber is sized to correspond to one cell, with the core size ranging from 2 to 10, and the cladding ranging from 10 to 30. The laser pulse travels through a fiber core which is coated with the materials and ablates a portion of a targeted cell or cellular component membrane. In addition, as the laser pulse exits the fiber, it imparts energy and momentum to the materials applied to the end of the fiber.

7399743, Jul 15, 2008

Oct 24, 2002

10/279733

Cheng Liu - Carlsbad CA, US
Thomas S. Edgington - La Jolla CA, US

The Scripps Research Institute - La Jolla CA

A61K 38/16
A61K 38/36

514 12

The invention provided compositions and methods to initiate site-specific thrombosis in tumor vasculature. The present invention also provides methods for using the disclosed compositions and methods to treat tumors.

7608591, Oct 27, 2009

Nov 29, 2005

11/288978

Cheng Liu - Carlsbad CA, US
Thomas S. Edgington - La Jolla CA, US

The Scripps Research Institute - La Jolla CA

A61K 38/00
A61K 38/14
C07K 9/00
A61K 38/04

514 18, 514 8, 514 17, 530322, 530330

The present invention relates to new agents and methods useful for preventing, treating and diagnosing diseases such as cancer. For example, the invention relates to prodrug agents useful for targeting and delivering cytotoxic drugs to cancerous cells.

20070264194, Nov 15, 2007

Aug 9, 2002

10/486318

Cheng Liu - Carlsbad CA, US
Thomas Edgington - La Jolla CA, US
Margaret Prescott - Milburn NJ, US

The Scripps Research Institute - La Jolla CA

A61K 38/08
A61K 38/00
A61K 49/00
A61P 9/00
C07H 21/00
C07K 1/00
G01N 33/53

424009200, 435007210, 514015000, 514016000, 514002000, 530300000, 530328000, 530329000, 536022100

The present invention provides peptides that selectively bind to mammalian atherosclerotic lesions. The present invention also provides methods for in vivo identification of peptides capable of binding to biomolecules as well as methods for identifying the targets of such binding moieties. Methods to diagnose or treat pathologic conditions that involve atherosclerotic lesions are also provided by the invention that involve administering to a mammal a peptide attached to a reporter molecule or a therapeutic agent, respectively.

20090175873, Jul 9, 2009

May 29, 2008

12/156123

Cheng Liu - Carlsbad CA, US

The Scripps Research institute - La Jolla CA

A61K 39/395
C07K 7/06
C07K 16/00
A61K 38/08
A61P 35/00

4241391, 530329, 5303879, 514 17

The present invention relates to new compositions and methods useful for preventing, treating and diagnosing metastatic and/or invasive cancer and undesirable angiogenesis. For example, the invention relates to inhibitors of proteases that are specifically expressed in tumors, prodrugs activated in the tumor microenvironment and methods for using those inhibitors and prodrugs to inhibit angiogenesis and tumor cell invasion.

20100113328, May 6, 2010

Oct 23, 2009

12/589572

Cheng Liu - Carlsbad CA, US
Thomas S. Edgington - La Jolla CA, US

The Scripps Research Institute - La Jolla CA

A61K 38/02
C07K 4/10
C07K 5/00
C07K 5/06
C07K 5/08
C12N 5/00
C07K 5/10
A61P 35/00

514 2, 530300, 530322, 530330, 530331, 435410

The present invention relates to new agents and methods useful for preventing, treating and diagnosing diseases such as cancer. For example, the invention relates to prodrug agents useful for targeting and delivering cytotoxic drugs to cancerous cells.

52614107, Nov 16, 1993

Feb 7, 1991

7/651449

Robert R. Alfano - Bronx NY
Cheng H. Liu - Flushing NY
Wenling S. Glassman - Bronx NY

A61B 600

128664

A method for determining if a tissue is a malignant tumor tissue, a benign tumor tissue, or a normal or benign tissue. The present method is based on the discovery that, when irradiated with a beam of infrared, monochromatic light, malignant tumor tissue, benign tumor tissue, and normal or benign tissue produce distinguishable Raman spectra. For human breast tissue, some salient differences in the respective Raman spectra are the presence of four Raman bands at a Raman shift of about 1078, 1300, 1445, and 1651 cm. sup. -1 for normal or benign tissue, the presence of three Raman bands at a Raman shift of about 1240, 1445, and 1659 cm. sup. -1 for benign tumor tissue, and the presence of two Raman bands at a Raman shift of about 1445 and 1651 cm. sup. -1 for malignant tumor tissue. In addition, it was discovered that for human breast tissue the ratio of intensities of the Raman bands at a Raman shift of about 1445 and 1659 cm. sup.

52938727, Mar 15, 1994

Apr 3, 1991

7/678637

Robert R. Alfano - Bronx NY
Cheng H. Liu - Flushing NY

A61B 600

128664

A method for distinguishing between calcified atherosclerotic tissue and either fibrous atherosclerotic tissue or normal cardiovascular tissue. The present method is based on the discovery that, when irradiated with a beam of monochromatic infrared light, calcified atherosclerotic human aortic tissue produces a Fourier Transform Raman spectrum which is distinguishable from analagous spectra obtained from fibrous atherosclerotic human aortic tissue and normal human aortic tissue. Some salient differences in the respective Raman spectra are the presence of five Raman bands at Raman shifts of 957, 1071, 1262-1300, 1445, and 1659 cm. sup. -1 (. +-. 4 cm. sup. -1 for all shifts) for the calcified tissue as compared to three Raman bands at Raman shifts of 1247-1270, 1453 and 1659 cm. sup. -1 (. +-. 4 cm. sup. -1 for all shifts) for the fibrous tissue and three Raman bands at Raman shifts of 1247-1270, 1449 and 1651 cm. sup. -1 (. +-. 4 cm. sup. -1 for all shifts) for the normal tissue.